Research on the new coronavirus vaccine has become a global event for researchers, the vaccine previously developed in Oxford, England, has largely failed, and the first adenovirus vaccine developed in China has just received good news.
The lancet is the world's top academic journal in the field of medicine. It has published a lot of papers on covid-19 new coronavirus research in the world before. The paper just released is jointly developed by academician Chen Wei of the Military Medical Research Institute and kangxinuo company,The clinical trial was officially announced on March 17 this year This is a new recombinant coronavirus vaccine (adenovirus vector)(
According to the data of the lancet, the vaccine is safe and well tolerated in phase I clinical period, and can generate immune response against sars-cov-2 in human body.
Among the 108 volunteers currently participating in the trial, promising results were shown after 28 days, and the final results will be evaluated within 6 months. However, further tests are needed to determine whether the immune response can effectively prevent sars-cov-2 infection.
This paper published by the lancet is the first human clinical data of new coronavirus vaccine in the world, which is of great significance. Although there is still six months to evaluate the final results, the current achievements are undoubtedly optimistic in vaccine research and development at home and abroad.